

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)



(10) International Publication Number
WO 2025/101863 A9

(51) International Patent Classification:

International Patent Classification:
A61K 47/54 (2017.01) **A61P 19/08 (2006.01)**
A61P 19/00 (2006.01)

(21) International Application Number:

PCT/US2024/055072

(22) International Filing Date:

08 November 2024 (08.11.2024)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) Priority Data:



63/597,246	08 November 2023 (08.11.2023)	US
63/623,961	23 January 2024 (23.01.2024)	US
63/651,801	24 May 2024 (24.05.2024)	US
63/660,347	14 June 2024 (14.06.2024)	US
63/695,491	17 September 2024 (17.09.2024)	US
63/711,678	24 October 2024 (24.10.2024)	US

(71) Applicant: **BIOMARIN PHARMACEUTICAL INC.**
[US/US]; 105 Digital Drive, Novato, CA 94949 (US).

(72) **Inventors: JAKARIA, Golam;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **CHOU, Tian, Wei;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **BOURBON, Pauline;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **ARAYA, Kidisti;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **CAMPBELL, Colm;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **MITCHELL, Nina, V.;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **CHARMANT, Olivier;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US). **WENDT, Daniel, Jr.;** c/o Biomarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949 (US).

(54) Title: CNP VARIANTS, CONJUGATES AND FORMULATIONS THEREOF

CNP conjugate with lipid moiety, glutamic acid, spacer, and electronic linker



CNP conjugate with lipid moiety, glutamic acid, spacer, and peptoid linker

Figure 1

(57) Abstract: Provided herein are pharmaceutical compositions comprising variants and prodrugs of C-type natriuretic peptide (CNP) disclosed herein. Also provided herein are methods of using the disclosed compositions in treating bone-related disorders or skeletal dysplasia, as well as pharmaceutical kits comprising the disclosed compositions.

[Continued on next page]

WO 2025/101863 A9

(74) **Agent: NEVILLE, Katherine, L.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) **Date of publication of this corrected version:**
21 August 2025 (21.08.2025)

(15) **Information about Correction:**
see Notice of 21 August 2025 (21.08.2025)